EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Clinical characteristics and HLA associations of azithromycin‐induced liver injury

Caroline Conlon, Yi-Ju Li, Jawad Ahmad iD, Huiman Barnhart, Robert J Fontana, Marwan Ghabril iD, Paul H Hayashi, David E Kleiner, William M Lee iD, Victor Navarro, Joseph A Odin, Elizabeth J Phillips and 4 more

Alimentary Pharmacology & Therapeutics · 2024-09 · 60 (6) · 787-795

DOI: 10.1111/apt.18160 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, published online on 2024-07-10. Written by Caroline Conlon and 15 co-authors. Institution: Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Major MEDLINE topics: Chemical and Drug Induced Liver Injury, Azithromycin, Anti-Bacterial Agents. Cited 18 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: NIDDK NIH HHS, NHGRI NIH HHS, NIMH NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Azithromycin (AZ) is a widely used antibiotic. The aim of this study was to characterise the clinical features, outcomes, and HLA association in patients with drug‐induced liver injury (DILI) due to AZ.

Methods

The clinical characteristics of individuals with definite, highly likely, or probable AZ‐DILI enrolled in the US Drug‐Induced Liver Injury Network (DILIN) were reviewed. HLA typing was performed using an Illumina MiSeq platform. The allele frequency (AF) of AZ‐DILI cases was compared to population controls, other DILI cases, and other antibiotic‐associated DILI cases.

Results

Thirty cases (4 definite, 14 highly likely, 12 probable) of AZ‐DILI were enrolled between 2004 and 2022 with a median age of 46 years, 83% white, and 60% female. Median duration of AZ treatment was 5 days. Latency was 18.5 days. 73% were jaundiced at presentation. The injury pattern was hepatocellular in 60%, cholestatic in 27%, and mixed in 3%. Ten cases (33%) were severe or fatal; 90% of these were hepatocellular. Two patients required liver transplantation. One patient with chronic liver disease died of hepatic failure. Chronic liver injury developed in 17%, of which 80% had hepatocellular injury at onset. HLA‐DQA1*03:01 was significantly more common in AZ‐DILI versus population controls and amoxicillin‐clavulanate DILI cases (AF: 0.29 vs. 0.11, p = 0.001 and 0.002, respectively).

Conclusion

Azithromycin therapy can lead to rapid onset of severe hepatic morbidity and mortality in adult and paediatric populations. Hepatocellular injury and younger age were associated with worse outcomes. HLA‐DQA1*03:01 was significantly more common in AZ cases compared to controls.

Subjects

MeSH terms (MEDLINE)

Chemical and Drug Induced Liver InjuryAzithromycinAnti-Bacterial AgentsHumansFemaleMaleMiddle AgedAdultAgedYoung AdultHLA AntigensAdolescentGene FrequencyHLA-DQ alpha-Chains

Author keywords

allelecausalitychronic liver injurydrug‐induced liver injury

Substances

AzithromycinAnti-Bacterial AgentsHLA AntigensHLA-DQA1 antigenHLA-DQ alpha-Chains

Authors and institutions

  • Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • Duke Clinical Research Institute, Durham, North Carolina, USA.
  • Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Division of Hepatology and Nutrition, Food and Drug Administration, Silver Spring, Maryland, USA.

ORCID profiles: Jawad Ahmad, Marwan Ghabril, William M Lee, Raj Vuppalanchi

Funding

  • NIDDK NIH HHS
  • NHGRI NIH HHS
  • NIMH NIH HHS
  • NCI NIH HHS
  • NIA NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Cite

APA

Conlon, C., Li, Y. J., Ahmad, J., Barnhart, H., Fontana, R. J., Ghabril, M., Hayashi, P. H., Kleiner, D. E., Lee, W. M., Navarro, V., Odin, J. A., Phillips, E. J., Stolz, A., Vuppalanchi, R., Halegoua-DeMarzio, D., & Drug‐Induced Liver Injury Network (DILIN) (2024). Clinical characteristics and HLA associations of azithromycin‐induced liver injury. Alimentary Pharmacology & Therapeutics, 60(6), 787-795. https://doi.org/10.1111/apt.18160

Vancouver

Conlon C, Li YJ, Ahmad J, Barnhart H, Fontana RJ, Ghabril M, et al. Clinical characteristics and HLA associations of azithromycin‐induced liver injury. Alimentary Pharmacology & Therapeutics. 2024;60(6):787-795. doi:10.1111/apt.18160

BibTeX
@article{Conlon2024,
  author = {Conlon, Caroline and Li, Yi-Ju and Ahmad, Jawad and Barnhart, Huiman and Fontana, Robert J and Ghabril, Marwan and Hayashi, Paul H and Kleiner, David E and Lee, William M and Navarro, Victor and Odin, Joseph A and Phillips, Elizabeth J and Stolz, Andrew and Vuppalanchi, Raj and Halegoua-DeMarzio, Dina and Drug‐Induced Liver Injury Network (DILIN), Drug‐Induced Liver Injury Network (DILIN)},
  title = {Clinical characteristics and HLA associations of azithromycin‐induced liver injury},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {60},
  number = {6},
  pages = {787--795},
  doi = {10.1111/apt.18160}
}
Start for free →